Table 1 Patient characteristics (n = 75)
RT/CCRT | ||||||
|---|---|---|---|---|---|---|
NFT | EBRT | EBRT + BRA | EBRT (CCRT) | EBRT + BRA (CCRT) | CT | |
n = 46 | n = 10 | n = 9 | n = 2 | n = 3 | n = 5 | |
Age (years) | 46.8 (27–78) | 44.7 (27–67) | 49.9 (31–69) | 63.5 (55–72) | 38.0 (33–43) | 53.0 (34–66) |
Follow-up time (months) | 78.7 (51–118) | 90.6 (64–117) | 77.8 (24–120) | 98.0 (61–135) | 113.3 (110–117) | 86.8 (61–134) |
Tumor size | ||||||
<2 cm | 6 (13.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) |
2 cm ≤ tumor < 4 cm | 40 (87.0 %) | 10 (100.0 %) | 9 (100.0 %) | 2 (100.0 %) | 3 (100.0 %) | 5 (100.0 %) |
Histologic type | ||||||
Squamous | 31 (67.4 %) | 10 (100.0 %) | 9 (100.0 %) | 1 (50.0 %) | 0 (0.0 %) | 0 (0.0 %) |
Adenocarcinoma | 12 (26.1 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (50.0 %) | 2 (66.7 %) | 5 (100.0 %) |
Adenosquamous | 3 (6.5 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (33.3 %) | 0 (0.0 %) |
Stromal invasion | ||||||
<1/2 | 24 (52.2 %) | 3 (30.0 %) | 2 (22.2 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) |
≥1/2 | 22 (47.8 %) | 7 (70.0 %) | 7 (77.8 %) | 2 (100.0 %) | 3 (100.0 %) | 5 (100.0 %) |
Lymphovascular invasion | ||||||
– | 37 (80.4 %) | 1 (10.0 %) | 3 (33.3 %) | 0 (0.0 %) | 1 (33.3 %) | 1 (20.0 %) |
+ | 9 (19.6 %) | 9 (90.0 %) | 6 (66.7 %) | 2 (100.0 %) | 2 (66.7 %) | 4 (80.0 %) |